Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment
Abstract Background Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. Methods We retrospectively analyzed testing in patients deemed...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgery 2018-04, Vol.215 (4), p.686-692 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 692 |
|---|---|
| container_issue | 4 |
| container_start_page | 686 |
| container_title | The American journal of surgery |
| container_volume | 215 |
| creator | Kozick, Zachary Hashmi, Ammar Dove, James Hunsinger, Marie Arora, Tania Wild, Jeffrey Shabahang, Mohsen Blansfield, Joseph |
| description | Abstract Background Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. Methods We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. Results A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test. Non-testing rose with age. White patients were more likely to be tested (56%) versus black patients (46%, p |
| doi_str_mv | 10.1016/j.amjsurg.2017.05.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1909220766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961017305706</els_id><sourcerecordid>2017296169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-3720cede6e62fc329b2cd0d2fe6fdcf1eaec7e1535f1d0adf93ed867dbb10f653</originalsourceid><addsrcrecordid>eNqFkktv1DAUhS0EokPhJ4AssWGTcO1M7IQFqMzwkiq6KJXYWY59Qz3khe1QzYbfXocZuuiGlR_6zrXvOZeQ5wxyBky83uW634XZ_8g5MJlDmQNUD8iKVbLOWFUVD8kKAHhWCwYn5EkIu3RkbF08Jie8EiAkyBX5s3Vh0t5Fh4G6gZqxnzqnB4P0xsVrGq-RXgxmjPsJ6fY7bTzqEKlZCE8jpn1SLdTV4CJaehl1un1Dz-hXHd046I5uDvBWR03f64BUh4Ah9DjEp-RRq7uAz47rKbn6-OHb5nN2fvHpy-bsPDPrdRWzQnIwaFGg4K0peN1wY8HyFkVrTctQo5HIyqJsmQVt27pAWwlpm4ZBK8rilLw61J38-GtOv1a9Cwa7Tg84zkGxGmrOQQqR0Jf30N04-9RHUIvTPPkp6kSVB8r4MQSPrZq867XfKwZqCUjt1DGgvzIFpUoBJd2LY_W56dHeqf4lkoB3BwCTHb8dehWMw2SgdR5NVHZ0_33i7b0KpnODM7r7iXsMd90wFbgCdblMyTIkTBZQShDFLYQDunY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2017296169</pqid></control><display><type>article</type><title>Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kozick, Zachary ; Hashmi, Ammar ; Dove, James ; Hunsinger, Marie ; Arora, Tania ; Wild, Jeffrey ; Shabahang, Mohsen ; Blansfield, Joseph</creator><creatorcontrib>Kozick, Zachary ; Hashmi, Ammar ; Dove, James ; Hunsinger, Marie ; Arora, Tania ; Wild, Jeffrey ; Shabahang, Mohsen ; Blansfield, Joseph</creatorcontrib><description>Abstract Background Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. Methods We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. Results A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test. Non-testing rose with age. White patients were more likely to be tested (56%) versus black patients (46%, p < 0.0001). Testing was highest at academic facilities (40%). Privately insured patients were more likely to get the test compared to uninsured (45 versus 34%, p < 0.0001). Those in the highest income quartile were more likely to be tested (p < 0.001). Conclusions ODX is under-utilized, with racial and socio-economic factors influencing testing. Further studies are necessary to identify ways to remove disparities and increase testing when appropriate. Summary This study uses the National Cancer Data Base to analyze compliance with the NCCN guidelines for Oncotype DX. Compliance with testing was thirty-six percent. Several factors influenced testing in our study, including facility type, racial and socio-economic factors.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2017.05.008</identifier><identifier>PMID: 28606707</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Biomarkers ; Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms - epidemiology ; Breast Neoplasms - ethnology ; Breast Neoplasms - genetics ; Cancer therapies ; Chemotherapy ; Clinical medicine ; Compliance ; Databases, Factual ; Decision making ; Disparities ; Economic factors ; Endocrine therapy ; Epidermal growth factor ; Female ; Gene expression ; Gene Expression Profiling - statistics & numerical data ; Guideline Adherence ; Healthcare Disparities - ethnology ; Healthcare Disparities - statistics & numerical data ; Humans ; Lymphatic system ; Middle Aged ; Oncotype DX ; Patients ; Population ; Population Surveillance ; Professionals ; Retrospective Studies ; Risk analysis ; Social factors ; Socioeconomic Factors ; Surgery ; Systematic review ; United States</subject><ispartof>The American journal of surgery, 2018-04, Vol.215 (4), p.686-692</ispartof><rights>Elsevier Inc.</rights><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Apr 1, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-3720cede6e62fc329b2cd0d2fe6fdcf1eaec7e1535f1d0adf93ed867dbb10f653</citedby><cites>FETCH-LOGICAL-c448t-3720cede6e62fc329b2cd0d2fe6fdcf1eaec7e1535f1d0adf93ed867dbb10f653</cites><orcidid>0000-0001-6660-2037 ; 0000-0002-7778-2130</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002961017305706$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28606707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kozick, Zachary</creatorcontrib><creatorcontrib>Hashmi, Ammar</creatorcontrib><creatorcontrib>Dove, James</creatorcontrib><creatorcontrib>Hunsinger, Marie</creatorcontrib><creatorcontrib>Arora, Tania</creatorcontrib><creatorcontrib>Wild, Jeffrey</creatorcontrib><creatorcontrib>Shabahang, Mohsen</creatorcontrib><creatorcontrib>Blansfield, Joseph</creatorcontrib><title>Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Abstract Background Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. Methods We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. Results A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test. Non-testing rose with age. White patients were more likely to be tested (56%) versus black patients (46%, p < 0.0001). Testing was highest at academic facilities (40%). Privately insured patients were more likely to get the test compared to uninsured (45 versus 34%, p < 0.0001). Those in the highest income quartile were more likely to be tested (p < 0.001). Conclusions ODX is under-utilized, with racial and socio-economic factors influencing testing. Further studies are necessary to identify ways to remove disparities and increase testing when appropriate. Summary This study uses the National Cancer Data Base to analyze compliance with the NCCN guidelines for Oncotype DX. Compliance with testing was thirty-six percent. Several factors influenced testing in our study, including facility type, racial and socio-economic factors.</description><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - ethnology</subject><subject>Breast Neoplasms - genetics</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Compliance</subject><subject>Databases, Factual</subject><subject>Decision making</subject><subject>Disparities</subject><subject>Economic factors</subject><subject>Endocrine therapy</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Profiling - statistics & numerical data</subject><subject>Guideline Adherence</subject><subject>Healthcare Disparities - ethnology</subject><subject>Healthcare Disparities - statistics & numerical data</subject><subject>Humans</subject><subject>Lymphatic system</subject><subject>Middle Aged</subject><subject>Oncotype DX</subject><subject>Patients</subject><subject>Population</subject><subject>Population Surveillance</subject><subject>Professionals</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Social factors</subject><subject>Socioeconomic Factors</subject><subject>Surgery</subject><subject>Systematic review</subject><subject>United States</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkktv1DAUhS0EokPhJ4AssWGTcO1M7IQFqMzwkiq6KJXYWY59Qz3khe1QzYbfXocZuuiGlR_6zrXvOZeQ5wxyBky83uW634XZ_8g5MJlDmQNUD8iKVbLOWFUVD8kKAHhWCwYn5EkIu3RkbF08Jie8EiAkyBX5s3Vh0t5Fh4G6gZqxnzqnB4P0xsVrGq-RXgxmjPsJ6fY7bTzqEKlZCE8jpn1SLdTV4CJaehl1un1Dz-hXHd046I5uDvBWR03f64BUh4Ah9DjEp-RRq7uAz47rKbn6-OHb5nN2fvHpy-bsPDPrdRWzQnIwaFGg4K0peN1wY8HyFkVrTctQo5HIyqJsmQVt27pAWwlpm4ZBK8rilLw61J38-GtOv1a9Cwa7Tg84zkGxGmrOQQqR0Jf30N04-9RHUIvTPPkp6kSVB8r4MQSPrZq867XfKwZqCUjt1DGgvzIFpUoBJd2LY_W56dHeqf4lkoB3BwCTHb8dehWMw2SgdR5NVHZ0_33i7b0KpnODM7r7iXsMd90wFbgCdblMyTIkTBZQShDFLYQDunY</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Kozick, Zachary</creator><creator>Hashmi, Ammar</creator><creator>Dove, James</creator><creator>Hunsinger, Marie</creator><creator>Arora, Tania</creator><creator>Wild, Jeffrey</creator><creator>Shabahang, Mohsen</creator><creator>Blansfield, Joseph</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6660-2037</orcidid><orcidid>https://orcid.org/0000-0002-7778-2130</orcidid></search><sort><creationdate>20180401</creationdate><title>Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment</title><author>Kozick, Zachary ; Hashmi, Ammar ; Dove, James ; Hunsinger, Marie ; Arora, Tania ; Wild, Jeffrey ; Shabahang, Mohsen ; Blansfield, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-3720cede6e62fc329b2cd0d2fe6fdcf1eaec7e1535f1d0adf93ed867dbb10f653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - ethnology</topic><topic>Breast Neoplasms - genetics</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Compliance</topic><topic>Databases, Factual</topic><topic>Decision making</topic><topic>Disparities</topic><topic>Economic factors</topic><topic>Endocrine therapy</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Profiling - statistics & numerical data</topic><topic>Guideline Adherence</topic><topic>Healthcare Disparities - ethnology</topic><topic>Healthcare Disparities - statistics & numerical data</topic><topic>Humans</topic><topic>Lymphatic system</topic><topic>Middle Aged</topic><topic>Oncotype DX</topic><topic>Patients</topic><topic>Population</topic><topic>Population Surveillance</topic><topic>Professionals</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Social factors</topic><topic>Socioeconomic Factors</topic><topic>Surgery</topic><topic>Systematic review</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kozick, Zachary</creatorcontrib><creatorcontrib>Hashmi, Ammar</creatorcontrib><creatorcontrib>Dove, James</creatorcontrib><creatorcontrib>Hunsinger, Marie</creatorcontrib><creatorcontrib>Arora, Tania</creatorcontrib><creatorcontrib>Wild, Jeffrey</creatorcontrib><creatorcontrib>Shabahang, Mohsen</creatorcontrib><creatorcontrib>Blansfield, Joseph</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kozick, Zachary</au><au>Hashmi, Ammar</au><au>Dove, James</au><au>Hunsinger, Marie</au><au>Arora, Tania</au><au>Wild, Jeffrey</au><au>Shabahang, Mohsen</au><au>Blansfield, Joseph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>215</volume><issue>4</issue><spage>686</spage><epage>692</epage><pages>686-692</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>Abstract Background Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. Methods We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. Results A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test. Non-testing rose with age. White patients were more likely to be tested (56%) versus black patients (46%, p < 0.0001). Testing was highest at academic facilities (40%). Privately insured patients were more likely to get the test compared to uninsured (45 versus 34%, p < 0.0001). Those in the highest income quartile were more likely to be tested (p < 0.001). Conclusions ODX is under-utilized, with racial and socio-economic factors influencing testing. Further studies are necessary to identify ways to remove disparities and increase testing when appropriate. Summary This study uses the National Cancer Data Base to analyze compliance with the NCCN guidelines for Oncotype DX. Compliance with testing was thirty-six percent. Several factors influenced testing in our study, including facility type, racial and socio-economic factors.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28606707</pmid><doi>10.1016/j.amjsurg.2017.05.008</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-6660-2037</orcidid><orcidid>https://orcid.org/0000-0002-7778-2130</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 2018-04, Vol.215 (4), p.686-692 |
| issn | 0002-9610 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1909220766 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Biomarkers Biomarkers, Tumor Breast cancer Breast Neoplasms - epidemiology Breast Neoplasms - ethnology Breast Neoplasms - genetics Cancer therapies Chemotherapy Clinical medicine Compliance Databases, Factual Decision making Disparities Economic factors Endocrine therapy Epidermal growth factor Female Gene expression Gene Expression Profiling - statistics & numerical data Guideline Adherence Healthcare Disparities - ethnology Healthcare Disparities - statistics & numerical data Humans Lymphatic system Middle Aged Oncotype DX Patients Population Population Surveillance Professionals Retrospective Studies Risk analysis Social factors Socioeconomic Factors Surgery Systematic review United States |
| title | Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A02%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disparities%20in%20compliance%20with%20the%20Oncotype%20DX%20breast%20cancer%20test%20in%20the%20United%20States:%20A%20National%20Cancer%20Data%20Base%20assessment&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Kozick,%20Zachary&rft.date=2018-04-01&rft.volume=215&rft.issue=4&rft.spage=686&rft.epage=692&rft.pages=686-692&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2017.05.008&rft_dat=%3Cproquest_cross%3E2017296169%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2017296169&rft_id=info:pmid/28606707&rft_els_id=S0002961017305706&rfr_iscdi=true |